English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Conservative treatments for this population are mainly based on progestin therapies, of which medroxyprogesterone acetate (MPA) and megestrol acetate (MA) systematic therapy are the classic regimens [1]. However, the therapeutic effects of MPA or MA are not yet optimal [2,3]. The complete response (CR) rate is 70%–80% in EEC and EAH patients after a median treatment period of 6–9 months using MPA or MA. The most common side effects are weight gain, headache, and vaginal spotting. Thrombosis also occurs in some patients using high dose progestins, which could be serious and life-threatening.

journal of gynecologic oncology

The current situation of the levonorgestrel intrauterine system (LNG-IUS) in conservative treatment for patients with early-stage endometrial cancer and atypical hyperplasia